Evaluation of radioiodine therapy with fixed doses of 10 and 15 mCi in patients with Graves' disease

被引:12
作者
Canadas, Viviane [1 ]
Vilar, Lucio [1 ]
Moura, Euane [1 ]
Brito, Ana [1 ]
Castellar, Enio [1 ]
机构
[1] Univ Fed Pernambuco, Hosp Clin, Serv Endocrinol, Recife, PE, Brazil
关键词
Graves' disease; hyperthyroidism; radioiodine; antithyroid drugs;
D O I
10.1590/S0004-27302007000700008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The treatment options for the hyperthyroidism of Graves' disease are antithyroid drugs, surgery and radioiodine, none of which is considered ideal, as they do not act directly on the etiopathogenesis of the disease. Radioiodine has been increasingly used as the treatment of choice because it is a safe and definitive therapy whose administration is very easy. Some authors prefer to administer higher doses in order to deliberately induce hypothyroidism, while others recommend lower doses that result in a lower incidence of hypothyroidism and a greater incidence of euthyroidism. There is no consensus for the optimal regimen of fixed doses to be used and this is the main focus of the present study, where doses of 10 and 15 mCi of I-131 were compared. Among the 164 patients analyzed, 61 (37.2%) were submitted to 10 mCi and 103 (62.8%) to 15 mCi. In the longitudinal analysis it was observed that remission of the hyperthyroidism was statistically different in the sixth month (p < 0.001), being higher in the group that used the dose of 15 mCi, but similar in both groups at 12 and 24 months. It may be concluded that the administration of fixed doses of 10 and 15 mCi of I-131 brought about a similar remission of the hyperthyroidism after 12 months of treatment. Moreover, the remission rate of the hyperthyroidism had no association with age, sex or previous therapy with antithyroid drugs.
引用
收藏
页码:1069 / 1076
页数:8
相关论文
共 46 条
[1]   A systematic review of drug therapy for Graves' hyperthyroidism [J].
Abraham, P ;
Avenell, A ;
Park, CM ;
Watson, WA ;
Bevan, JS .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 153 (04) :489-498
[2]   An update on the pharmacological management of hyperthyroidism due to Graves' disease [J].
Bartalena, L ;
Tanda, ML ;
Bogazzi, F ;
Piantanida, E ;
Lai, A ;
Martino, E .
EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) :851-861
[3]   Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy [J].
Bartalena, L ;
Marcocci, C ;
Bogazzi, F ;
Manetti, L ;
Tanda, ML ;
Dell'Unto, E ;
Bruno-Bossio, G ;
Nardi, M ;
Bartolomei, MP ;
Lepri, A ;
Rossi, G ;
Martino, E ;
Pinchera, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (02) :73-78
[4]   USE OF CORTICOSTEROIDS TO PREVENT PROGRESSION OF GRAVES OPHTHALMOPATHY AFTER RADIOIODINE THERAPY FOR HYPERTHYROIDISM [J].
BARTALENA, L ;
MARCOCCI, C ;
BOGAZZI, F ;
PANICUCCI, M ;
LEPRI, A ;
PINCHERA, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (20) :1349-1352
[5]   Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease [J].
Bogazzi, F ;
Bartalena, L ;
Campomori, A ;
Brogioni, S ;
Traino, C ;
De Martino, F ;
Rossi, G ;
Lippi, F ;
Pinchera, A ;
Martino, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (10) :4490-4495
[6]   Drug therapy: Antithyroid drugs [J].
Cooper, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (09) :905-917
[7]   Antithyroid drugs in the management of patients with Graves' disease: An evidence-based approach to therapeutic controversies [J].
Cooper, DS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (08) :3474-3481
[8]   Hyperthyroidism [J].
Cooper, DS .
LANCET, 2003, 362 (9382) :459-468
[9]   Radioiodine and the immune system [J].
Degroot, LJ .
THYROID, 1997, 7 (02) :259-264
[10]   Radioiodine treatment of hyperthyroidism -: Prognostic factors affecting outcome [J].
Erem, C ;
Kandemir, N ;
Hacihasanoglu, A ;
Ersöz, HO ;
Ukinc, K ;
Kocak, M .
ENDOCRINE, 2004, 25 (01) :55-60